Discovery Portfolio ::

Under the discovery program, our R&D Center has discovered some very promising molecules and patent applications for these molecules have been filed in India, under the PCT and the US. As shown in the graphic below, Torrent R&D Center is working on a variety of discovery projects.



Our Advanced Stage Molecules::
AGE Breaker:
AGE (Advanced Glycosylation End-products) breaker compound in Phase-II global clinical trial; has potential in correcting diabetic complications like neuropathy, nephropathy, retinopathy and heart failure. Phase-I clinical trial was successfully conducted in India and UK. Phase II Clinical Trial is about to commence in India, Europe, Russia and Serbia.

T2 Analog:
The T2 Analog Compound has a potential to emerge as a safer therapy for the treatment of metabolic syndrome and associated cardiovascular risk reduction. A part of Phase I clinical trial is in progress in European Union and another part is about to commence in India.


Development Portfolio::

Within a span of 5 years, the major achievements to the credit of the Torrent R&D Centre are the development of world class fermentation technology for Pen-G, synthesis of Omeprazole, Sparfloxacin, Nicorandil, Lamotrigine, Sertraline, Sildenafil Citrate, Repaglinide, Rosiglitazone, Clopidogrel, Sibutramine and Cerivastatin and the introduction of low dose combination of Lisinopril and Hydrochlorothiazide(Listril Plus/Forte), matching international quality standards. This rational combination was specifically formulated keeping in mind the needs of Indian patients.

First Time Introduction by the Centre :

• Fluconazole 0.3% Eye Drops for the first time in the world.
• Esomeprazole (20,40mg) Multi Unit Particulate System (Pellets compressed in the form of tablet) for the first time in India.
• Rosiglitazoe 2mg/4mg Immediate Release + Metformin 500mg Sustanded - Release Dual Retard Technology launched in the form of Inlay Tablet for the first time of India.
• Few Non-Conventional Dosage Forms Developed